CheckMate914

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial

CheckMate914

SIU 2019: Adjuvant Therapy for High-risk Renal Cell Carcinoma: Current Status

Singer

ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments

Oncology Journals review - For healthcare professionals only

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

CheckMate914